Amylyx Pharmaceuticals, Inc. (AMLX) EBITDA
- 2026-06-30: Basis Reported; EBITDA (m); Operating income -$45.69M; Depreciation and amortization (m).
- 2026-03-31: Basis Reported; EBITDA (m); Operating income -$43.78M; Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA (m); Operating income -$36.03M; Depreciation and amortization (m).
- 2025-06-30: Basis Reported; EBITDA (m); Operating income -$42.86M; Depreciation and amortization (m).
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | Reported | (m) | -$45.69M | (m) | (m) | (m) | (m) | -$31.42M* | (m) | $23.77M | $21.93M | (m) |
| 2026-03-31 | Reported | (m) | -$43.78M | (m) | (m) | (m) | (m) | -$36.88M | (m) | $27.61M | $16.17M | (m) |
| 2025-09-30 | Reported | (m) | -$36.03M | (m) | $0.00 | (m) | $24.00K* | -$30.37M* | $0.00 | $19.86M | $16.17M | $0.00 |
| 2025-06-30 | Reported | (m) | -$42.86M | (m) | $0.00 | (m) | $17.00K* | -$25.25M* | $0.00 | $27.22M | $15.64M | $0.00 |
| 2025-03-31 | Reported | (m) | -$37.80M | (m) | $0.00 | (m) | $11.00K | -$39.82M | $0.00 | $22.12M | $15.68M | $0.00 |
| 2024-09-30 | Reported | (m) | -$75.66M | (m) | $416.00K | (m) | -$19.00K* | -$41.57M* | $0.00 | $21.24M | $17.83M | $0.00 |
| 2024-06-30 | Reported | (m) | -$76.29M | (m) | -$1.02M | (m) | $89.00K* | -$66.58M* | $8.00K | $23.35M | $21.65M | $0.00 |
| 2024-03-31 | Reported | (m) | -$122.13M | (m) | $88.64M | (m) | $67.00K | -$489.00K | $5.95M | $36.61M | $57.76M | $242.00K |
| 2023-09-30 | Reported | (m) | $18.72M | (m) | $102.69M | (m) | $357.00K* | -$5.17M* | $5.22M | $30.04M | $48.72M | $1.52M |
| 2023-06-30 | Reported | (m) | $20.20M | (m) | $98.22M | (m) | $278.00K* | $8.61M* | $5.58M | $29.04M | $43.39M | $1.93M |
| 2023-03-31 | Reported | (m) | -$2.05M | (m) | $71.43M | (m) | $250.00K | -$5.07M | $5.28M | $24.19M | $44.01M | -$170.00K |
| 2022-09-30 | Reported | (m) | -$54.68M | (m) | $345.00K | (m) | $459.00K* | -$43.08M* | $172.00K | $24.91M | $29.94M | -$125.00K |
| 2022-06-30 | Reported | (m) | -$54.25M | (m) | (m) | (m) | $1.10M* | -$46.46M* | (m) | $24.26M | $29.99M | $174.00K |
| 2022-03-31 | Reported | (m) | -$47.81M | (m) | (m) | (m) | $342.00K | -$40.63M | (m) | $21.46M | $26.35M | $146.00K |
| 2021-09-30 | Reported | (m) | -$22.92M | (m) | (m) | (m) | $153.00K* | -$20.86M* | (m) | $12.85M | $10.35M | (m) |
| 2021-06-30 | Reported | (m) | -$18.59M | (m) | (m) | (m) | $0.00* | -$13.05M* | (m) | $10.93M | (m) | (m) |
| 2021-03-31 | Reported | (m) | -$12.87M | (m) | (m) | (m) | $14.00K | -$12.64M | (m) | $6.86M | (m) | (m) |
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | Reported | (m) | -$153.29M | (m) | $0.00 | (m) | $138.00K | -$123.34M | $0.00 | $90.40M | $62.89M | $46.00K |
| 2024-12-31 | Reported | (m) | -$314.73M | (m) | $87.37M | (m) | $157.00K | -$167.65M | $5.95M | $104.08M | $114.33M | -$393.00K |
| 2023-12-31 | Reported | (m) | $38.80M | (m) | $380.79M | (m) | $1.24M | $11.92M | $25.44M | $128.19M | $188.36M | $5.03M |
| 2022-12-31 | Reported | (m) | -$201.34M | (m) | $22.23M | (m) | $2.53M | -$179.87M | $2.99M | $93.45M | $127.13M | $774.00K |
| 2021-12-31 | Reported | (m) | -$82.69M | (m) | (m) | (m) | $353.00K | -$74.80M | (m) | $44.04M | $38.93M | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |